CDK9 PROTAC Degraders with Tunable Linkers for Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
CDK9 is difficult to therapeutically inhibit with small molecules due to its similar catalytic ATP-binding cleft structure, making selective inhibition challenging, particularly in cancers like acute myeloid leukemia and acute lymphoblastic leukemia.
Innovation Solution
Development of CDK9 degraders that include a CDK9 binding moiety, such as AT7519 or VIP152, conjugated to an E3 ubiquitin ligase binding moiety, such as thalidomide, lenalidomide, or pomalidomide, to promote the ubiquitination and degradation of CDK9 through cellular machinery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are used to target CDK9, then the catalytic activity of CDK9 can be inhibited, but selective inhibition is challenging due to similar catalytic ATP-binding cleft structure across kinases
Solution Approach 1:
The patent segments the inhibition strategy into two distinct components: a CDK9-specific binding moiety (AT7519 or VIP152) that targets the unique structural features of CDK9, and an E3 ligase binding moiety (thalidomide, lenalidomide, or pomalidomide) that recruits the degradation machinery. This segmentation allows each component to be optimized independently for its specific function, achieving selective CDK9 inhibition without affecting other kinases with similar catalytic clefts.
Solution Approach 2:
The patent introduces an intermediary mechanism - the PROTAC molecule itself - that mediates between the CDK9 binding moiety and the E3 ligase binding moiety. This intermediary PROTAC structure enables selective CDK9 targeting by first binding to CDK9 with high affinity, then recruiting the E3 ligase to facilitate degradation, thereby overcoming the selectivity challenge posed by similar catalytic structures.
2Reliability
If PROTACs are used to target CDK9 for degradation, then selective protein elimination is achieved, but the molecular structure becomes more complex
Solution Approach 1:
The PROTAC molecule is segmented into two distinct functional moieties: a CDK9 binding moiety (AT7519 or VIP152) that provides selective target recognition, and an E3 ligase binding moiety (thalidomide, lenalidomide, or pomalidomide) that provides degradation capability. This segmentation allows each part to be optimized for its specific function while maintaining overall molecular manageability.
Solution Approach 2:
The patent employs a universal PROTAC platform approach where the same E3 ligase binding moieties (thalidomide, lenalidomide, pomalidomide) can be combined with different CDK9 binding moieties (AT7519 or VIP152) to create multiple degraders with similar degradation mechanisms. This multi-functionality allows the E3 ligase recruitment function to be reused across different CDK9 degrader variants.
3Productivity
If the linker length and structure are optimized, then the potency and solubility of the degrader are improved, but the synthesis complexity increases
Solution Approach 1:
The patent systematically varies key parameters of the linker structure (length, chemical composition, flexibility) to optimize the balance between degrader potency, solubility, and synthesis feasibility. By changing these parameters across different degrader variants, the patent identifies optimal linker configurations that achieve desired pharmacological properties while remaining amenable to synthesis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CDK9 degraders effectively induce the degradation of CDK9, providing a therapeutic approach for treating cancers like acute myeloid leukemia and acute lymphoblastic leukemia.
Implementation Method 1
The E3 ligase then recruits an E2 conjugating enzyme to the ternary complex. The E2 is then able to ubiquitinate the target protein, labelling an available lysine residue on the protein
Implementation Method 2
The poly-ubiquitinated target protein is recognized and degraded by the proteasome
Data Source
AI summary
Described herein are CDK9 degraders that include a CDK9 binding moiety, such as AT7519 or VIP152, conjugated to a E3 ubiquitin ligase binding moiety, such as thalidomide, lenalidomide, or pomalidomide. These degraders can induce the ubiquitination of CDK9 and promote its degradation in cells. The linker covalently tethering the CDK9 binding moiety to the E3 ubiquitin ligase binding moiety can be selected to tune the solubility profile and potency of the degrader. Accordingly, the present disclosure provides compounds, compositions, kits, uses, and methods for the treatment of cancer (e.g., blood cancers such as acute myeloid leukemia or acute lymphoblastic leukemia).